Elixinol Wellness Delivers Revenue Growth and Cash Flow Improvement in Q4 FY25
Elixinol Wellness Limited (ASX: EXL) reported a constructive operational performance for Q4 FY25, reflecting the benefits of cost optimisation, portfolio refinement and a stronger emphasis on higher-margin distribution channels. Quarterly revenue reached AU$ 4.1 million, representing a 9.5% increase quarter-on-quarter, supported by seasonal demand and continued expansion in direct-to-consumer sales. Full-year revenue improved compared with FY24, driven by a more focused retail footprint and improved product mix. The Company achieved underlying operating cash flow positivity during the quarter following a reduction of approximately 30% in the operating cost base relative to Q4 FY24. E-commerce performance, led by The Healthy Chef, delivered improved margins through product innovation and premium positioning. With a leaner cost structure and diversified revenue streams, Elixinol enters FY26 positioned to pursue sustainable profitability and scalable growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Elixinol Wellness Delivers Revenue Growth and Cash Flow Improvement in Q4 FY25
Elixinol Wellness Limited (ASX: EXL) reported a constructive operational performance for Q4 FY25, reflecting the benefits of cost optimisation, portfolio refinement and a stronger emphasis on higher-margin distribution channels. Quarterly revenue reached AU$ 4.1 million, representing a 9.5% increase quarter-on-quarter, supported by seasonal demand and continued expansion in direct-to-consumer sales. Full-year revenue improved compared with FY24, driven by a more focused retail footprint and improved product mix. The Company achieved underlying operating cash flow positivity during the quarter following a reduction of approximately 30% in the operating cost base relative to Q4 FY24. E-commerce performance, led by The Healthy Chef, delivered improved margins through product innovation and premium positioning. With a leaner cost structure and diversified revenue streams, Elixinol enters FY26 positioned to pursue sustainable profitability and scalable growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au